Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 2297

Journal of Obesity & Weight Loss Therapy received 2297 citations as per Google Scholar report

Journal of Obesity & Weight Loss Therapy peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • Centre for Agriculture and Biosciences International (CABI)
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • CABI full text
  • Cab direct
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • University of Bristol
  • Pubmed
  • ICMJE
Share This Page

Substantial weight loss in 237 hypogonadal men with obesity class I-III under long-term treatment with testosterone undecanoate (TU): Observational real-life data from a registry study

Euro Global Summit & Medicare Expo on Weight Loss

Farid Saad

Posters-Accepted Abstracts: J Obes Weight Loss Ther

DOI: 10.4172/2165-7904.S1.015

Abstract

Background: Testosterone (T) and obesity are inversely associated. Obesity has a greater impact on T decrease than advancing age.
Methods: Single-center, prospective, cumulative registry study of 340 hypogonadal men (total T ≤12.1 nmol/L and presence of
symptoms). 237 men with obesity class I-III were analyzed. All men received TU injections every 3 months for up to 7 years.
Anthropometric parameters were measured at every 3-monthly visit.
Results: Class I (n=103, mean age: 58 years): Weight decreased from 102.79 to 85.41 kg by 17.27 kg, per cent change from baseline
-16.71%. Waist circumference (WC) decreased from 104.74 to 95.24 cm by 8.93 cm. BMI decreased from 32.85 to 27.65 kg/m2 by
5.5 kg/m2. Class II (n=97, mean age: 60 years): Weight decreased from 116.67 to 92.19 kg by 25.15 kg, per cent change from baseline
-21.52%. WC decreased from 111.97 to 100.96 cm by 12.53 cm. BMI decreased from 37.33 to 29.88 kg/m2 by 8.06 kg/m2. Class III
(n=36, mean age: 60 years): Weight decreased from 128.92 to 100.75 kg by 29.3 kg, per cent change from baseline -22.79%. WC
decreased from 117.56 to 103.63 cm by 12.93 cm. BMI decreased from 41.99 to 33.23 kg/m2 by 9.59 kg/m2. No patient gained or
re-gained weight. No patient dropped out. There were no major adverse cardiovascular events during the entire observation period.
Conclusions: All changes were clinically meaningful and sustained for the full observation period. T therapy is an effective approach
to achieve sustained weight loss in obese hypogonadal men, thereby potentially reducing cardiometabolic risk.

Biography

Farid Saad worked for various Pharmaceutical companies as specialist for reproductive endocrinology, pediatric endocrinology, andrology, endocrinology of male ageing,
and hormonal male contraception in clinical development andrology, scientific and medical affairs. He currently works for Bayer Pharma in Berlin, Germany. He has authored
and co-authored more than 100 peer-reviewed papers and more than 500 scientific abstracts. He received honorary Professorships in clinical research and endocrinology
at Gulf Medical University, Ajman, UAE, and at Men’s Health Reproduction Study Center, Hang Tuah University, Surabaya, Indonesia.

Relevant Topics
Top